[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:renal-failure":3},{"name":4,"total":5,"recruiting":6,"trials":7,"biomarkers":127,"states":128},"Renal Failure",18,10,[8,16,23,30,37,43,49,56,62,68,74,82,88,94,101,107,113,121],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT06056102","CAR-T Cell Therapy for Desensitization in Kidney Transplantation",[12],"Phase 1","RECRUITING","2026-08-26T02:18:26.932189Z","2026-07-05T05:32:16.746896Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT04128189","Shingrix in Renal Transplant Recipients",[20],"Phase 3","2026-08-26T02:15:28.524219Z","2026-05-05T02:43:28.345727Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":28,"content_modified":29},"NCT04240054","Bortezomib, Isatuximab, Cyclophosphamide and Dexamethasone Induction in Transplant-Eligible Multiple Myeloma Patients With Renal Insufficiency",[27],"Phase 2","2026-08-26T02:19:16.454910Z","2026-05-05T02:43:27.920390Z",{"nct_id":31,"title":32,"phases":33,"status":13,"updated_at":35,"content_modified":36},"NCT06142396","Pilot Study Dara-CyBorD in Newly Diagnosed Multiple Myeloma Patients With Renal Failure",[34],"Early Phase 1","2026-08-26T02:17:44.240289Z","2026-05-05T02:43:27.606533Z",{"nct_id":38,"title":39,"phases":40,"status":13,"updated_at":41,"content_modified":42},"NCT06337942","Deceased Donor Bladder or Combined Kidney-bladder Transplantation: a Phase 0 First-in-human Study",[],"2026-08-26T02:17:35.666428Z","2026-05-05T02:43:29.077282Z",{"nct_id":44,"title":45,"phases":46,"status":13,"updated_at":47,"content_modified":48},"NCT03723564","Serial Amnioinfusions as Regenerative Therapy for Pulmonary Hypoplasia",[12],"2026-08-26T02:18:17.007929Z","2026-05-05T02:43:26.758872Z",{"nct_id":50,"title":51,"phases":52,"status":13,"updated_at":54,"content_modified":55},"NCT06714864","Open-Label Study to Assess Safety and Time to Catheter-related Bloodstream Infections (CRBSI) in Subjects From Birth to \u003C 18 Years of Age",[53],"Phase 4","2026-08-26T02:16:23.080181Z","2026-05-05T02:43:28.960088Z",{"nct_id":57,"title":58,"phases":59,"status":13,"updated_at":60,"content_modified":61},"NCT07194395","Contactless Optical Monitoring of AV Access Using the PatenSee System in Outpatient Hemodialysis Patients",[],"2026-08-26T02:17:45.190188Z","2026-05-13T02:55:06.670806Z",{"nct_id":63,"title":64,"phases":65,"status":13,"updated_at":66,"content_modified":67},"NCT01524276","Product Surveillance Registry",[],"2026-08-26T02:16:14.341106Z","2026-05-13T02:55:06.078749Z",{"nct_id":69,"title":70,"phases":71,"status":13,"updated_at":72,"content_modified":73},"NCT07293936","Post-Filter Hematocrit",[],"2026-08-26T02:15:17.167444Z","2026-05-05T02:35:31.759532Z",{"nct_id":75,"title":76,"phases":77,"status":79,"updated_at":80,"content_modified":81},"NCT06866236","Use of New Drug QRX-3 for Prevention and Treatment of Chronic Kidney Disease Progression",[78],"Phase 2\u002FPhase 3","NOT_YET_RECRUITING","2026-08-26T02:16:29.226604Z","2026-05-05T02:43:29.141357Z",{"nct_id":83,"title":84,"phases":85,"status":79,"updated_at":86,"content_modified":87},"NCT07358195","Addition of Venetoclax to Combined Hematopoietic Stem Cell and Kidney Transplantation",[34],"2026-08-26T02:17:57.997171Z","2026-05-05T02:43:26.926016Z",{"nct_id":89,"title":90,"phases":91,"status":79,"updated_at":92,"content_modified":93},"NCT05592847","A Study of the Effect of a Nurse Navigator Program on High Risk Patients",[],"2026-08-26T02:16:06.684983Z","2026-05-05T02:43:29.228993Z",{"nct_id":95,"title":96,"phases":97,"status":98,"updated_at":99,"content_modified":100},"NCT07341516","Worldwide Assessment of Deceased Donor Kidney Utilization",[],"ENROLLING_BY_INVITATION","2026-08-26T02:16:09.452956Z","2026-06-16T05:54:07.879522Z",{"nct_id":102,"title":103,"phases":104,"status":98,"updated_at":105,"content_modified":106},"NCT05952999","Analysis of the Virtual Acute Care at Home Experience",[],"2026-08-26T02:19:01.741747Z","2026-06-16T05:54:08.093987Z",{"nct_id":108,"title":109,"phases":110,"status":98,"updated_at":111,"content_modified":112},"NCT05443321","Advancing Health Information Exchange (HIE) During Inter-hospital Transfer (IHT) to Improve Patient Outcomes",[],"2026-08-26T02:16:04.914942Z","2026-06-16T05:54:08.032266Z",{"nct_id":114,"title":115,"phases":116,"status":118,"updated_at":119,"content_modified":120},"NCT05687058","Empagliflozin in ESKD - A Feasibility Study",[117],"Phase 1\u002FPhase 2","ACTIVE_NOT_RECRUITING","2026-08-03T01:56:19.375288Z","2026-05-05T02:43:28.498919Z",{"nct_id":122,"title":123,"phases":124,"status":118,"updated_at":125,"content_modified":126},"NCT03615235","APOL1 Long-term Kidney Transplantation Outcomes Network (APOLLO)",[],"2026-08-03T03:25:38.640645Z","2026-05-13T02:55:06.173925Z",[],[129,133,137,140,143,147,150,153,156,159,162],{"state":130,"count":131,"slug":132},"Massachusetts",6,"massachusetts",{"state":134,"count":135,"slug":136},"California",4,"california",{"state":138,"count":135,"slug":139},"Georgia","georgia",{"state":141,"count":135,"slug":142},"Texas","texas",{"state":144,"count":145,"slug":146},"Alabama",3,"alabama",{"state":148,"count":145,"slug":149},"Florida","florida",{"state":151,"count":145,"slug":152},"Michigan","michigan",{"state":154,"count":145,"slug":155},"New York","new-york",{"state":157,"count":145,"slug":158},"Pennsylvania","pennsylvania",{"state":160,"count":145,"slug":161},"Tennessee","tennessee",{"state":163,"count":145,"slug":164},"Wisconsin","wisconsin"]